The ICCVS Team has recently attended the COST Action IMMUNO-model CA21135 annual conference in Warsaw, Poland (13th-14th May 2025). The initiative aims to foster research and innovation in the field of preclinical immuno-oncology models, advancing cancer treatment for patients by improving their outcomes and quality of life. IMMUNO-model brings together European researchers from diverse sectors (academia, clinical, industry) with the common goal of establishing a network that endorses immuno-oncology research by specifically promoting the sharing, standardization, and application of immunotherapy preclinical models. The meeting has opened several collaborative opportunities for the clinical peptidomics group in the fields of cytokines, secretome analysis, immunopeptidome analysis for glycopeptides, 2D/3D model proteomics, peptide/protein biomarker discovery, and further development of in silico modeling.
In addition, this Action will enable the establishment of a broad, creative, and collaborative hub through the organization of community-building activities, the creation of synergies among European and non-European scientists, and the training of future researchers in the field. This Action aims to contribute to translating novel scientific discoveries into benefits for cancer patients and society. ICCVS Team, including prof. Natalia Marek-Trzonkowska, dr hab. eng. Monikaben Padariya, dr Anna Biernacka, and dr Sachin Kote actively participated in the keynote speaker and poster presentation sessions, initiating collaborative opportunities. The efforts of the COST action will enhance the design of in vitro and in vivo experiments in the cancer field, thereby overcoming the limitations previously encountered in cancer immunotherapy.
COST Action IMMUNO-model CA21135 annual conference participants
dr hab. eng. Monikaben Padariya (ICCVS) during the poster session
The participation was financed by COST and CANVAS project.
